脑脊液Aβ38水平与阿尔茨海默病相关认知下降风险的关联
在瑞典BioFINDER和ADNI两个临床队列共656人中,基线脑脊液Aβ38水平较高与AD生物标志物阳性者MMSE下降较慢及转化为AD痴呆风险较低相关;作者认为γ-分泌酶调节剂可能作为疾病修饰治疗。
要点
- 脑脊液Aβ38水平较高与AD生物标志物阳性者MMSE下降较慢相关。
- BioFINDER队列中Aβ38较高与转化为AD痴呆风险较低相关(HR 0.83/SD)。
- ADNI队列中Aβ38较高与MMSE下降较少相关,但与转化风险无显著关联。
核心结论
- 在两个独立临床队列中,较高的脑脊液Aβ38水平与AD相关改变风险较低相关。
- 作者认为这些发现提示γ-分泌酶调节剂可能作为疾病修饰治疗有效。
研究设计与样本
- 在瑞典BioFINDER研究和阿尔茨海默病神经影像学倡议(ADNI)两个临床队列共656人中测量脑脊液Aβ38水平。
- 采用Cox回归模型评估基线Aβ38水平与AD生物标志物阳性(AD+;由脑脊液磷酸化tau[P-tau]/Aβ42比值确定)伴主观认知下降(SCD)或轻度认知障碍(MCI)者AD痴呆风险的关联。
- 采用线性混合效应模型评估基线Aβ38水平与AD+伴SCD、MCI或AD痴呆者认知下降(以简易精神状态检查[MMSE]测量)的关联。
主要发现
- BioFINDER队列中,高Aβ38水平与MMSE评分下降较慢相关(β=0.30分/SD,p=0.001)。
- BioFINDER队列中,高Aβ38水平与转化为AD痴呆风险较低相关(风险比0.83/SD,p=0.03)。
- ADNI队列中,较高Aβ38水平与MMSE评分下降较少相关(β=0.27,p=0.01),但与转化至AD痴呆风险无显著关联(p=0.66)。
- 两个队列中,进一步校正脑脊液P-tau或脑脊液Aβ42水平后,Aβ38水平仍与认知和临床结局显著相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Experimental studies suggest that the balance between short and long β-amyloid (Aβ) species might modulate the toxic effects of Aβ in Alzheimer disease (AD), but clinical evidence is lacking. We studied whether Aβ38 levels in CSF relate to risk of AD dementia and cognitive decline. METHODS: CSF Aβ38 levels were measured in 656 individuals across 2 clinical cohorts: the Swedish BioFINDER study and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cox regression models were used to evaluate the association between baseline Aβ38 levels and risk of AD dementia in AD biomarker-positive individuals (AD+; determined by CSF phosphorylated tau [P-tau]/Aβ42 ratio) with subjective cognitive decline (SCD) or mild cognitive impairment (MCI). Linear mixed-effects models were used to evaluate the association between baseline Aβ38 levels and cognitive decline as measured by the Mini-Mental State Examination (MMSE) in AD+ participants with SCD, MCI, or AD dementia. RESULTS: In the BioFINDER cohort, high Aβ38 levels were associated with slower decline in MMSE score (β = 0.30 points per SD, p = 0.001) and with lower risk of conversion to AD dementia (hazard ratio 0.83 per SD, p = 0.03). In the ADNI cohort, higher Aβ38 levels were associated with less decline in MMSE score (β = 0.27, p = 0.01) but not risk of conversion to AD dementia (p = 0.66). Aβ38 levels in both cohorts were significantly associated with both cognitive and clinical outcomes when further adjusted for CSF P-tau or CSF Aβ42 levels. DISCUSSION: Higher CSF Aβ38 levels are associated with lower risk of AD-related changes in 2 independent clinical cohorts. These findings suggest that γ-secretase modulators could be effective as disease-altering therapy. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT03174938.
引用
- Cullen N, Janelidze S, Palmqvist S, et al. Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline. Neurology. 2021. PMID: 34937781. doi:10.1212/WNL.0000000000013228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。